Seelos Therapeutics, Inc.
SEEL · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | $8,558 | $215,828 | $509,133 | $3,187,303 |
| - Cash | $294 | $524 | $2,996 | $2,584 |
| + Debt | $10,157 | $13,137 | $14,228 | $16,907 |
| Enterprise Value | $18,421 | $228,441 | $520,365 | $3,201,626 |
| Revenue | $376 | $579 | $653 | $406 |
| % Growth | -35.1% | -11.3% | 60.8% | – |
| Gross Profit | -$379 | $564 | $638 | $392 |
| % Margin | -100.8% | 97.4% | 97.7% | 96.6% |
| EBITDA | $1,748 | -$2,626 | -$5,419 | $10,554 |
| % Margin | 464.9% | -453.5% | -829.9% | 2,599.5% |
| Net Income | $1,710 | -$2,664 | -$5,453 | $10,498 |
| % Margin | 454.8% | -460.1% | -835.1% | 2,585.7% |
| EPS Diluted | 0.12 | -0.72 | -1.47 | 2.13 |
| % Growth | 116.7% | 51% | -169% | – |
| Operating Cash Flow | -$972 | -$4,642 | -$1,911 | -$5,749 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$972 | -$4,642 | -$1,911 | -$5,749 |